

REMARKS

Claims 8-11 are pending. Claims 1-7 and 12-30 have been cancelled without prejudice.

Claims 8-11 have been amended to put the claims in a form suitable for allowance. Support for the amendments can be found through out the specification, for example, See paragraphs [0011] to [0016] and Figures 6 and 7. It is believed that the amended claims still fall within the group of claims elected for examination.

In response to the restriction requirement, the applicants have elected claims 8-11 of Group 6 without traverse. The claims of Group 6 are drawn to methods for treating obesity by using compounds that effect a reduction in the expression of Slc25a10, which in particular embodiments can be siRNA.

The applicants elect the combinations of siRNA that can bind to mRNA transcribed from the human Slc25a10 gene. Accordingly, the applicants have cancelled without prejudice the siRNA that bind to mRNA transcribed from the mouse Slc25a10 gene. The applicants elect as a species of siRNA for examination purposes the combination of siRNA set forth in SEQ ID NOs:9 and 10.

Favorable action is earnestly solicited.

CONDITIONAL PETITION

Applicant hereby makes a Conditional Petition for any relief available to correct any defect in connection with this filing, or any defect remaining in this application after this filing. The Commissioner is authorized to charge deposit account 13-2755 for the petition fee and any other fee(s) required to effect this Conditional Petition.

Respectfully submitted,

By /John David Reilly, Reg. #43,039/  
JOHN DAVID REILLY  
Reg. No. 43,039  
Attorney for Applicant

MERCK & CO., INC.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-6914

Date: July 8, 2009